Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00352742
Status:
TERMINATED
Last Update Posted:
2008-10-28
First Post:
2006-07-13
Brief Title:
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
Sponsor:
Attenuon
Organization:
Attenuon
Study Overview
Official Title:
A Phase III Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib
Status:
TERMINATED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to describe the safety and effect of ATN-224 in combination with bortezomib Velcade in patients with Multiple Myeloma who are relapsed from or refractory to bortezomib
Detailed Description:
Multiple myeloma is a bone marrow based malignancy of plasma cells that is highly treatable but rarely curable Angiogenesis defined as the growth of new blood vessels from pre-existing vessels is a requirement for the growth of nearly all tumors An increase in bone marrow angiogenesis is present in Multiple Myeloma and correlates with disease progression Several new therapies that target angiogenic pathways have shown clinical efficacy ATN-224 is a small molecule that has been shown in pre-clinical studies to be antiangiogenic
Using one agent to overcome resistance of another agent is a treatment regimen used in oncology A preclinical study with the combination of ATN-224 and bortezomib shows that the combination is more effective than either single agent in a bortezomib resistant cell line
Using one agent to overcome resistance of another agent is a treatment regimen used in oncology A preclinical study with the combination of ATN-224 and bortezomib shows that the combination is more effective than either single agent in a bortezomib resistant cell line
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None